Who this is for:
If you’ve had surgery for EGFR-mutated lung cancer — in Melbourne, Colombo, Kandy, Galle, Indonesia, the Philippines, or the Maldives — and are wondering whether further treatment is necessary, even when the cancer has been completely removed.
After lung cancer surgery, one of the hardest questions patients ask is:
“If everything has been removed, why do I still need treatment?”
This is a very reasonable question.
And for patients with EGFR-mutated lung cancer, the answer has changed significantly over the past few years.
What was the problem before?
Even when surgery removes all visible cancer,
microscopic cancer cells can still remain in the body.
These cells are:
• Too small to see on scans
• Silent for months or years
• But capable of growing back
When recurrence happens, it often appears:
• In the lungs
• Or in the brain
Traditionally:
• Chemotherapy helped a little
• But the risk of the cancer returning was still meaningful
What the ADAURA trial tested
The ADAURA trial looked at a very important question:
Can we reduce the chance of cancer coming back after surgery?
It included:
• Patients with early-stage EGFR-mutated lung cancer (stage IB–IIIA)
• All had complete surgical removal of their cancer
They were then given:
• Osimertinib (a targeted tablet) for 3 years
• Or a placebo (no active drug)
Results (what actually changed)
• ~80% reduction in recurrence risk
(Disease-free survival HR ~0.20)
• Improved overall survival
(HR ~0.49)
• Significant reduction in brain metastases
Why this matters — in real life
This is not just about delaying the cancer coming back.
For the right patient, this treatment:
• Dramatically reduces the chance of recurrence
• Protects the brain from future spread
• Improves long-term survival
This is particularly important for patients in:
• Sri Lanka (Colombo, Kandy, Galle)
• Indonesia, the Philippines, and the Maldives
Where access to coordinated care and follow-up can vary,
getting the right treatment at the right time becomes even more important.
What about side effects?
Osimertinib is generally well tolerated:
• Mild diarrhoea
• Skin rash
• Fatigue
Most patients are able to:
• Continue daily activities
• Maintain quality of life
• Stay on treatment long term
The important question: is this delaying cancer — or preventing it?
This has been one of the biggest debates.
Earlier, we were not sure if the treatment:
• Simply delayed recurrence
• Or truly improved long-term outcomes
Now, with updated data showing an overall survival benefit,
we can say with more confidence:
This treatment is changing outcomes, not just postponing relapse.
Where this fits today (2026)
• This is now standard of care globally, including Australia
• Requires molecular testing (EGFR testing) at diagnosis
• Typically given for 3 years after surgery
For patients travelling from:
• Sri Lanka, Indonesia, Philippines, Maldives
A coordinated plan (diagnosis → molecular testing → treatment access)
can often be organised through specialist centres in Melbourne.
A simple but important message
Many patients are told their cancer has been “removed.”
But in modern oncology,
removal is only the first step.
Understanding the biology of the cancer
is what determines what comes next.
Key Takeaway
Molecular testing remains critical — even in early-stage lung cancer [1,2]
Even after successful surgery, targeted treatment can significantly reduce the risk of the cancer returning.
For EGFR-mutated disease, osimertinib has changed expectations — from recurrence to long-term control, and in some cases, cure.
Key Evidence
1. What has genuinely changed in lung cancer treatment over the last 5–10 years
2. Why molecular testing at the beginning can change the entire course of lung cancer treatment
3. Wu YL, Tsuboi M, He J, et al. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020;383(18):1711–1723. doi:10.1056/NEJMoa2027071
4. Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023;389(2):137–147. doi:10.1056/NEJMoa2304594
Q and A
1. If my lung cancer was completely removed, why do I still need more treatment?
The “Microscopic” Factor: Even when a surgeon removes a visible tumour, “micrometastases” (invisible cancer cells) can remain in the bloodstream or nearby tissue. These cells are too small to be seen on CT or PET scans.
The Goal: Adjuvant therapy (treatment after surgery) acts as an “insurance policy” to target these silent cells before they can form a new tumour in the lungs or spread to the brain.
2. What is the ADAURA trial, and how does it change my outlook?
The Breakthrough: The ADAURA trial is a landmark global study involving patients with Stage IB–IIIA EGFR-mutated lung cancer. It tested a targeted tablet called Osimertinib against a placebo.
The Results: Research showed an 80% reduction in the risk of the cancer returning and a significant improvement in overall survival. In simple terms, it is currently the most effective way to keep the cancer away for longer.
3. Does every lung cancer patient need these tablets after surgery?
Mutation Specific: No. This treatment only works for patients whose cancer has a specific “typo” in its DNA called an EGFR mutation.
The Next Step: It is vital to ask your oncologist for molecular testing (biopsy testing) on the tumour that was removed. Even if you are in the early stages, knowing your EGFR status is the only way to know if you are eligible for this life-extending treatment.
4. What are the side effects, and will they impact my quality of life?
Manageability: Unlike traditional chemotherapy, Osimertinib is a “targeted” tablet taken once daily at home. Most patients in the trial maintained a high quality of life.
What to Expect: Common side effects include mild diarrhoea, skin rashes, or nail changes. Most of these are easily managed with over-the-counter creams or medications, allowing you to continue work, travel, and family life in Melbourne, Colombo, or Manila without the intense fatigue of chemo.